Trial run can predict who will adhere to HIV antiretrovirals
BY Advocate.com Editors
November 16 2002 1:00 AM ET
Participating in a two-week trial with mock medications before starting an actual anti-HIV drug regimen can predict how well a person will adhere to the regimen, with people who best followed dosing instructions ultimately having the best chances of achieving undetectable blood-based HIV viral loads, aidsmap.com reports. The study, conducted at two hospitals in South Carolina, showed that 75% of patients who were able to take 90% of their mock medications as directed during the two-week trial were able to achieve undetectable viral loads when given real anti-HIV drugs. Only about half of those who took less than 90% of their mock drugs on time had undetectable HIV viral loads on highly active antiretroviral therapy.
- Op-ed: 'Religious Discrimination' Laws Have Nothing to Do With Religion
- Mike Pence 'Abhors' Discrimination? His Record Shows Otherwise
- Ellen's 11 Most Uproarious, April Fool's-Approved Pranks
- Arrow and The Flash Stars: It's Time for a Gay Superhero on TV
- Indiana Newspaper Sends Big Message
- Subaru Comes Out Against Indiana's 'License to Discriminate'